Identifying factors that affect survival in Ewing Sarcoma patients
Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma
Istituto Ortopedico Rizzoli · NCT06243588
This study looks at how different factors like age and tumor size affect survival rates in people with Ewing sarcoma to help doctors create better treatment plans for patients at higher risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 2 Years and up |
| Sex | All |
| Sponsor | Istituto Ortopedico Rizzoli (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Bologna, BO) |
| Trial ID | NCT06243588 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the correlation between various factors such as age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation, and biomarkers with overall survival and relapse-free survival in patients diagnosed with Ewing sarcoma. By reviewing clinical records of patients treated at the Rizzoli Orthopaedic Institute over a 30-year period, the study seeks to identify reliable prognostic factors that could help in stratifying patients based on their risk levels. This information may lead to tailored treatment approaches for high-risk patients.
Who should consider this trial
Good fit: Ideal candidates for this study are male and female patients aged 2 years and older who have been diagnosed with Ewing sarcoma and have available clinical and imaging data.
Not a fit: Patients who do not meet the inclusion criteria, such as those without a diagnosis of Ewing sarcoma or lacking clinical data, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with Ewing sarcoma by identifying those at higher risk for poor outcomes.
How similar studies have performed: While the approach of identifying prognostic factors in Ewing sarcoma has been explored in other studies, this specific observational study may provide novel insights based on a comprehensive review of long-term clinical data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021 * Age ≥ 2 years * Diagnosis of Ewing Sarcoma * Patients with available clinical and imaging data Exclusion Criteria: * At least one inclusion criterion not met
Where this trial is running
Bologna, BO
- IRCCS Itituto Ortopedico Rizzoli — Bologna, BO, Italy (RECRUITING)
Study contacts
- Study coordinator: Costantino Errani
- Email: costantino.errani@ior.it
- Phone: 0516366
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ewing Sarcoma